explore -WSS

explore

author：Wikipedia 2025-09-06 01:58:53 - browse：5

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： There’s no way to know how good AI health technologies are

WSS

Peter Marks talks Operation Warp Speed for Rare Diseases

Obesity drugs seen as possible treatment for liver disease MASH

New documents shed light on MD Anderson Cancer Institute feud

PBM reform efforts get punted in Congress

Dario to buy mental health app maker Twill in cash and stock deal

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

explore

explore

focus

Moonlake's readout produced a cash windfall. Risks remain

How should state employee insurance handle Wegovy?

Heart attack and stroke risk calculators need revising

NIH study of ME/CFS points to clear biological hallmarks

Peter Hotez and the public health issue of online harassment

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

How to save PrEP access — and even expand it

Cancer cells are shown to suck energy source from immune cells

The high cost of giving birth even with insurance

Why palliative psychiatry is worth discussing

hotspot

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

A fraught question for the kids of Alzheimer’s: Is it coming for us?

A solution to the after

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Massive project maps cells in human brain in unprecedented detail

STAT readers on older presidents, polypills, Medicare, and more

leisure time

Wikipedia

Wikipedia

leisure time